



ISSN: 0975-833X

Available online at <http://www.journalcra.com>

INTERNATIONAL JOURNAL  
OF CURRENT RESEARCH

International Journal of Current Research  
Vol. 12, Issue, 03, pp.10436-10442, March, 2020

DOI: <https://doi.org/10.24941/ijcr.38263.03.2020>

## RESEARCH ARTICLE

### VALIDITY OF 2-DAY CARDIOPULMONARY EXERCISE TESTING IN FEMALE PATIENTS WITH MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME

\*C (Linda) MC van Campen and Frans C Visser

Stichting Cardiozorg, Planetenweg 5, 2132 HN Hoofddorp, NL

#### ARTICLE INFO

##### Article History:

Received 14<sup>th</sup> December, 2019

Received in revised form

10<sup>th</sup> January, 2020

Accepted 28<sup>th</sup> February, 2020

Published online 28<sup>th</sup> March, 2020

##### Key Words:

Chronic Fatigue Syndrome,  
Cardiopulmonary Exercise Testing,  
VO<sub>2</sub> peak, ventilatory Threshold, VO<sub>2</sub>AT,  
RER, Myalgic Encephalitis, Workload.

#### ABSTRACT

**Introduction:** Among the main characteristics of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are effort intolerance along with a prolonged recovery from exercise and post-exertional exacerbation of ME/CFS symptoms. The gold standard for measuring the severity of physical activity intolerance is cardiopulmonary exercise testing (CPET). Multiple studies have shown that peak oxygen consumption is reduced in the majority of ME/CFS patients. A consecutive day CPET protocol has shown a difference on day 2 in ME/CFS patients in contrast to sedentary controls. Because the studied numbers of female ME/CFS patients in the published literature, are not very extensive, the aim of this study was to examine whether the response to a 2-day CPET protocol in a larger sample of female ME/CFS patients was similar to that studied in other research teams.

**Methods:** From 102 female patients, 70 female ME/CFS patients fulfilled the criteria of a 2-day CPET protocol for analysis. Measures of oxygen consumption (VO<sub>2</sub>), heart rate (HR), systolic and diastolic blood pressure, workload (Work), and respiratory exchange ratio (RER) were made at maximal (peak) and ventilatory threshold (VT) intensities. Data were analysed using a paired t-test.

**Results:** Baseline characteristics of the group were as follows. Mean age was 44 (12) years, median BMI was 27.1(4.4)kg/m<sup>2</sup>. Median disease duration was 10 years (IQR 7-13). Heart rate, systolic and diastolic blood pressure at rest and the RER did not differ significantly between CPET 1 and CPET 2. All other CPET parameters at the ventilatory threshold and maximum exercise differed significantly (p-value between <0.005 and <0.0001). All patients experienced a deterioration of performance on CPET2 as measured by the predicted and actual VO<sub>2</sub> and workload at peak exercise and ventilatory threshold. **Conclusion:** This study confirms that female ME/CFS patients have a reduction in exercise capacity in response to a consecutive day CPET. These results are similar to published results in female ME/CFS populations.

Copyright © 2020, C (Linda) MC van Campen and Frans C Visser. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Citation:** C (Linda) MC van Campen and Frans C Visser. 2020. "Validity of 2-day cardiopulmonary exercise testing in female patients with myalgic encephalomyelitis/chronic fatigue syndrome", *International Journal of Current Research*, 12, (03), 10436-10442.

## INTRODUCTION

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a serious and potentially disabling chronic disease (Carruthers *et al.* 2011; Clayton 2015; Fukuda *et al.* 1994; IOM 2015). The exact pathophysiology has not been established but there is considerable evidence that ME/CFS is associated with abnormalities of the central and autonomic nervous systems, and that an association with infectious agents and immunological abnormalities is often present (Arnett *et al.* 2011; Gerrity *et al.* 2004; Gur and Oktayoglu 2008; Klimas *et al.* 1990; Komaroff and Cho 2011; Naess *et al.* 2010; Okamoto *et al.* 2012; Ortega-Hernandez and Shoenfeld 2009; Stewart 2000).

Abnormalities of energy metabolism also have been described (Fluge *et al.* 2016; Naviaux *et al.* 2016; Tomas *et al.* 2018; Wong *et al.* 1992). An important symptom of patients with ME/CFS is exercise intolerance along with a prolonged recovery from exercise (physical as well as mental) and post-exertional exacerbation of ME/CFS symptoms (IOM 2015), termed post-exertional malaise (PEM) (Jones *et al.* 2010; Paul *et al.* 1999). The pathophysiology of the exercise intolerance is not exactly known but involves both metabolic abnormalities of skeletal muscles as well as central nervous system abnormalities (Fulle *et al.* 2007; Gur and Oktayoglu 2008; Jones *et al.* 2010; McCully *et al.* 2006; McCully *et al.* 2003; Siemionow *et al.* 2004; Wong *et al.* 1992). The gold standard for measuring the severity of physical activity intolerance is cardiopulmonary exercise testing (CPET). Studies on ME/CFS patients have shown conflicting results on test results.

\*Corresponding author: C (Linda) MC van Campen,  
Stichting Cardiozorg, Planetenweg 5, 2132 HN Hoofddorp, NL.

Multiple studies have shown that peak oxygen consumption is reduced in the majority of ME/CFS patients (De Becker *et al.* 2000; Fulcher and White 2000; Hodges *et al.* 2018; Jammes *et al.* 2005; Keller *et al.* 2014; Sargent *et al.* 2002; Sisto *et al.* 1996; Snell *et al.* 2013; Vanness *et al.* 2007; Vermeulen *et al.* 2010; Vermeulen and Vermeulen van Eck 2014; Wallman *et al.* 2004). However, studies have also shown that a single CPET in ME/CFS patients may show that peak  $\text{VO}_2$  values are similar to or only slightly lower than those of healthy sedentary controls. A 2-day CPET protocol, with two CPET separated by 24 hours has confirmed that ME/CFS patients have significantly lower  $\text{VO}_2$  and workload parameters on day 2 (CPET 2) compared to day 1 (CPET 1). In contrast, sedentary controls have unaltered or slightly improved  $\text{VO}_2$  and workload (Keller *et al.* 2014; Lien *et al.* 2019; Nelson *et al.* 2019; Snell *et al.* 2013; Vanness *et al.* 2007; Vermeulen *et al.* 2010). Because of the relatively low number of female ME/CFS patients described in literature and a new recent finding in male ME/CFS patients on blood pressure differences in 2-day CPET protocols, the aim of this study was to examine the effect of a 2-day CPET protocol in female ME/CFS patients and to study blood pressure alterations on CPET day 2 compared to CPET day 1 in female ME/CFS patients.

**Patients, material and methods:** Participants were females with ME/CFS and performed a 2-day CPET protocol. All patients had a detailed clinical history to establish the diagnosis of ME/CFS according to the ME criteria (Caruthers *et al.* 2011) and CFS criteria of Fukuda (Fukuda *et al.* 1994). Of the 102 female patients undergoing CPET between June 2012 and August 2018, 4 were excluded because the ventilatory threshold could not accurately be determined, 25 only had a single CPET, and 3 patients had more than one test, but not on 2 consecutive days, leaving 70 female patients with data from a 2-day CPET protocol available for analysis. Alternative diagnoses which could explain the fatigue and other symptoms were ruled out in all patients. All patients gave informed consent to analyze their data. The use of clinical data for descriptive studies was approved by the ethics committee of the Slotervaart Hospital, the Netherlands (reference number P1736).

**Cardiopulmonary exercise testing (CPET):** Patients underwent a symptom-limited exercise test on a cycle ergometer (Excalibur, Lode, Groningen, The Netherlands) according to a previously described protocol (Van Campen 2020). A RAMP workload protocol was used varying between 10-30 Watt/min increases, depending on sex, age, and expected exercise intolerance. Oxygen consumption ( $\text{VO}_2$ ), carbon dioxide release ( $\text{VCO}_2$ ), and oxygen saturation were continuously measured (Cortex, Procure, The Netherlands), and displayed on screen using Metasoft software (Cortex, Biophysic GmbH, Germany). An ECG was continuously recorded and blood pressures were measured using the Nexfin device (BMEYE, Amsterdam, The Netherlands) (Martina *et al.* 2012). Cycle seat height was positioned to approximately 175° of knee extension, and the same seat height was used for both tests. Expired gases were collected breath-by-breath through a two-way breathing valve, and analyzed using open circuit spirometry. The metabolic measurement system (Cortex, Biophysic GmbH, Germany) was calibrated before each test with ambient air, standard gases of known concentrations, and a 3-L calibration syringe. The ventilatory threshold (VT), a measure of the anaerobic threshold, was

identified from expired gases using the V-Slope algorithm (Beaver *et al.* 1986). Ventilatory or anaerobic threshold is the exercise intensity at which metabolism transitions toward increased anaerobic energy production. The same experienced cardiologist supervised the test and performed visual assessment and confirmation of the algorithm-derived VT. Testing took place in a controlled environment with a temperature range of 20-24°C and 15-60% relative humidity. Patients were encouraged by standard phrases each minute to perform maximally to the point of exhaustion. The mean of the  $\text{VO}_2$  measurements of the last 15 seconds before ending the exercise (peak  $\text{VO}_2$ ) was taken.  $\text{VO}_2$  at the peak and at the VT as well as the heart rate (HT) at the peak exercise were expressed as a percentage of the normal values of a population study: %peak  $\text{VO}_2$ , %VT  $\text{VO}_2$  and %peak HR (Glaser *et al.* 2010). Also the mean respiratory exchange ratio (RER;  $\text{VCO}_2/\text{VO}_2$ ) of the last 15 seconds was calculated. Immediately after the test the attending cardiologist noted the primary reason for termination of the exercise.

**Statistical analysis:** Data were analyzed using the statistical package of Graphpad Prism version 6.05 (Graphpad software, La Jolla, California, USA). All continuous data were tested for normal distribution using the D'Agostino-Pearson omnibus normality test, and presented as mean (SD) or as median with the IQR, where appropriate. Because of the multiple comparisons a conservative p value of <0.01 was considered significant.

## RESULTS

Table 1 shows the characteristics of the study participants. Mean age was 41 (10) years, median BMI was 24.6(4.4)kg/m<sup>2</sup>. Median disease duration was 11 years (IQR 6-18). Thirty-eight female patients were diagnosed with fibromyalgia. According to the ICC criteria, 29 patients had mild disease, 27 patients had moderate disease and 14 patients had severe disease. Table 2 shows the parameters of the CPET of day 1 and day 2, the range of absolute differences between CPET 1 and 2 for CPET parameters at the ventilatory threshold and at peak exercise ( $\text{VO}_2$  peak, % $\text{VO}_2$  peak,  $\text{VO}_2$  VT, % $\text{VO}_2$  VT, WR peak and WR VT), and the percentage decline on day 2 compared to day 1. Only heart rate at rest and the RER did not differ significantly between CPET 1 and CPET 2. All other CPET parameters at the ventilatory threshold and maximum exercise differed significantly. Figure 1 shows the values of peak  $\text{VO}_2$  at CPET 1 and CPET 2 (panel A), %predicted peak  $\text{VO}_2$  at CPET 1 and CPET 2 (panel C),  $\text{VO}_2$  at the ventilatory threshold at CPET 1 and CPET 2 (panel B) and the %predicted  $\text{VO}_2$  at the ventilatory threshold for CPET 1 and CPET 2 (panel D). All values differed significantly ( $p < 0.0001$ ). Peak oxygen consumption changed from 19 (5) to 17 (6) ml/min/kg and oxygen consumption at the ventilatory threshold changed from 12 (2) to 9 (2) ml/min/kg. Figure 2 shows the workload graphs at peak exercise for CPET 1 and CPET 2 (panel A) and at the ventilatory threshold for CPET 1 and CPET 2 (panel B). Both values differed significantly ( $p < 0.0001$ ). Workload at peak exercise changed from 123 (29) to 108 (32) Watt and the workload at the ventilatory threshold changed from 62 (19) to 43 (18) Watt. Figure 3 is the graphic representation of the absolute differences in 6 CPET parameters from table 2. Figure 3 shows the differences in systolic and diastolic blood pressures both at rest and at peak exercise. All were significantly lower at the CPET test on day 2 compared to the

CPET test on day 1 (all  $p < 0.0001$ ). Systolic blood pressure at rest changed from 115 (30) to 109 (30) mmHg, diastolic blood pressure at rest changed from 78 (19) to 74 (19) mmHg. Systolic blood pressure at peak exercise changed from 150 (42) to 137 (41) mmHg and finally diastolic blood pressure at peak exercise changed from 93 (24) to 85 (23) mmHg.


## DISCUSSION

A two day CPET protocol in ME/CFS patients shows a unique feature of the disease: reduced CPET parameters as the  $VO_2$  peak and at the ventilatory threshold on the second day of the protocol, which is in contrast to the  $VO_2$  data in sedentary controls (Lien *et al.* 2019; Nelson *et al.* 2019; Snell *et al.* 2013; Vanness *et al.* 2007; Vermeulen *et al.* 2010). These findings of the lower  $VO_2$  at peak exercise on the second day in ME/CFS patients, compared to sedentary controls, makes it unlikely that this phenomenon is due to deconditioning (Nijs *et al.* 2004; Vanness *et al.* 2007), and suggests metabolic abnormalities. It may represent an early sign of post-exertional malaise (PEM) (IOM 2015), a cardinal feature of the disease. In studies analyzing the difference between day 1 and day 2 CPET in ME/CFS patients, a relatively limited numbers of patients have been studied, varying from 6 to 18 female patients (Keller *et al.* 2014; Lien *et al.* 2019; Nelson *et al.* 2019; Vanness *et al.* 2007; Vermeulen *et al.* 2010) and one somewhat larger female study population (Snell *et al.* 2013). We recently reported on a male ME/CFS patient (n=25) population as literature only reported 12 (5 and 7 respectively) male patients in two studies (Keller *et al.* 2014; Nelson *et al.* 2019; Van Campen 2020). To investigate whether males have a different CPET phenotype, we analyzed the response to CPET in a larger male ME/CFS patient sample. The main finding of this recent study was that in male ME/CFS patients, all measurements of  $VO_2$  and workload at the ventilatory threshold and at peak exercise were significantly lower on the second day CPET compared to the first day, similar to published findings in females. We studied a larger female ME/CFS patient population to additionally validate published results in female ME/CFS patients and to study the recently described changes in blood pressure differences between day 1 and 2 CPET studies in female ME/CFS patients. In the studied females similar significant findings on decline in systolic and diastolic blood pressure were found as described in male ME/CFS patients (Van Campen 2020). Additionally, we observed a lower heart rate at the ventilatory threshold, apart from lower heart rate at peak exercise on day 2 compared to day 1, in female ME/CFS patients as had been described earlier by Nelson *et al.* (Nelson *et al.* 2019) and as we described in male ME/CFS patients (Van Campen 2020).

**Cardiopulmonary exercise testing 2-day protocols: comparison to literature:** Vanness *et al.* (Vanness *et al.* 2007) studied 6 female CFS patients and 6 female sedentary controls in a two day CPET protocol. The first day peak  $VO_2$  was 26.2 (4.9) ml/min/kg for CFS patients and 28.4 (7.2) ml/min/kg for sedentary controls. The results for patients are higher than reported in our study. Age was not reported in this study, so differences might be due to a younger study population with less intense disease. This study documented a significant decline in  $VO_2$  peak and  $VO_2$  at ventilatory threshold at the second day. Our results in female ME/CFS patients are consistent with these findings.


Vermeulen *et al.* (Vermeulen *et al.* 2010) studied 15 female ME/CFS patients and 15 female controls in a two day CPET protocol. The peak  $VO_2$  was 22.3 (5.7) ml/min/kg for CFS patients and 31.2 (7.0) ml/min/kg in controls, patient results were somewhat higher in the female ME/CFS patient population of our study. The mean age of studied subjects was lower in this study (35.5 (11.9) years) which – together with hypothetically less intense diseased population – might account for the difference in peak oxygen consumption. At both day 1 and day 2 a significantly lower peak  $VO_2$  and  $VO_2$  at the ventilatory threshold was found in ME/CFS patients compared to controls. In ME/CFS patients there was a decrease between day 1 and day 2 in peak  $VO_2$  and an unaltered  $VO_2$  at the ventilatory threshold. Snell *et al.* (Snell *et al.* 2013) studied 51 female ME/CFS patients and 10 female controls. The peak  $VO_2$  in ME/CFS patients was 21.51 (4.09) ml/min/kg at day 1 and 20.44 (4.47) ml/min/kg at day 2. The most important difference between day 1 and day 2 was found to be a decrease in workload at the ventilatory threshold: for ME/CFS patients from 49.41 (20.40) Watt to 22.20 (18.05) Watt. The patient population included was older (46.29 (8.01) years) than the patient population in the present study. The higher value of oxygen consumption is probably different due to the inclusion from a less intense diseased patient population. Multivariate analysis showed no significant differences between control participants and participants with CFS for test 1. However, for test 2, participants with CFS reached significantly lower values for oxygen consumption and workload at peak exercise and at the ventilatory or anaerobic threshold.

Keller *et al.* (Keller *et al.* 2014) studied 22 CFS patients (17 females and 5 males) in a two day CPET protocol. No controls were included. The first day results for peak  $VO_2$  were 21.9 (4.75) ml/min/kg and percentage predicted  $VO_2$  peak 77.1 (20.22)%. Those results are slightly higher when compared to our study, probably due to gender differences in exercise values and the inclusion of several male ME/CFS patients. On day 2 results for peak  $VO_2$  were 18.6 (4.06) ml/min/kg and percentage predicted  $VO_2$  peak 65.2 (15.74)%. Differences between CPET 1 and CPET 2 from this study population show similar significant declines as we have found in the present study. Also,  $VO_2$  at the ventilatory threshold, peak workload and workload at the ventilatory threshold were all significantly lower on day 2. Nelson *et al.* studied 16 ME/CFS patients (9/7 female/male) and 10 controls (5/5 female/male) (Nelson *et al.* 2019). The peak  $VO_2$  results reported for patients were 27.3 (9.2) ml/min/kg which is higher than the results in the present study. The biggest change this study reported was a decline in workload at the ventilatory threshold (from 87.8 (29.6) to 72.5 (27.7) Watt). Decreases in maximum workload and peak oxygen consumption were non-significant, maybe due to the study population and the gender mix. This may also account for the differences in results compared to the present study, as well as maybe a less intense diseased study population. They concluded that a decrease of the workload at the ventilatory threshold in ME/CFS patients may represent an objective biomarker for the diagnosis of ME/CFS. Finally, Lien *et al.* included ME/CFS patients and controls: 18 patients and 15 controls completed the total study protocol (Lien *et al.* 2019). Peak  $VO_2$  and  $VO_2$  at the ventilatory threshold were significantly lower in ME/CFS patients on day 2 compared to day 1. Peak workload decreased significantly in ME/CFS patients comparing day 2 with day 1.




CPET: cardiopulmonary exercise test; VT: ventilatory (or anaerobic) threshold.

Figure 1. Peak oxygen consumption for CPET1 and CPET2 (panel A), the % predicted peak oxygen consumption for CPET1 and CPET2 (panel B), the oxygen consumption at ventilatory (anaerobic) threshold for CPET1 and CPET2 (Panel C) and the % predicted oxygen consumption at ventilatory threshold for CPET1 and CPET2 (Panel D)




CPET: cardiopulmonary exercise test; VT: ventilatory (or anaerobic) threshold.

Figure 2. Workload at peak exercise for CPET1 and CPET2 (panel A) and at the ventilatory threshold for CPET1 and CPET2 (panel B).



CPET: cardiopulmonary exercise test; VT: ventilatory (or anaerobic) threshold.

Figure 3. Range of absolute differences of CPET parameters, peak VO<sub>2</sub>, predicted % peak VO<sub>2</sub>, VO<sub>2</sub> at the ventilatory threshold, predicted % VO<sub>2</sub> at the ventilatory threshold (panel A), workload at the ventilatory threshold and workload at peak exercise (CPET 2 – CPET 1)(panel B)



CPET: cardiopulmonary exercise test.

Figure 4 Systolic blood pressure in rest for CPET1 and CPET2 (panel A), systolic blood pressure at peak exercise for CPET 1 and CPET 2 (panel B), diastolic blood pressure in rest for CPET1 and CPET2 (Panel C) and the diastolic blood pressure at peak exercise for CPET1 and CPET2 (Panel D)

Table 1. Baseline criteria

	Female ME/CFS (n=70)
Age in years	41(10)
Height in cm	170 (7)
Weight in kg	71 (13)
BSA in m <sup>2</sup>	1.4 (0.2)
BMI in kg/m <sup>2</sup>	24.6 (4.4)
Disease duration in years	11 (6-18)

BMI: body mass index (DuBois formula); BSA: body surface area. Mean (SD); Median (IQR)

Table 2. CPET1 and CPET2 variables for female ME/CFS patients

Peak exercise	CPET 1	CPET 2	Range of absolute differences CPET 2 – CPET 1	% difference CPET 2 – CPET 1	p-value
VO <sub>2</sub> peak in ml/min/kg	19 (5)	17 (6)	-7 to 6	-9 (14)	<0.0001
%pred VO <sub>2</sub> peak	69 (17)	63 (19)	-30 to 20	-9 (13)	<0.0001
HR rest in bpm	89 (13)	88 (12)		0 (9)	ns
HR peak in bpm	152 (19)	145 (22)		-5 (6)	<0.0001
SBP rest in mmHg	122 (13)	116 (14)		-5 (7)	<0.0001
SBP peak in mmHg	160 (19)	147 (22)		-8 (10)	<0.0001
DBP rest in mmHg	83 (9)	79 (9)		-4 (8)	<0.0001
DBP peak in mmHg	99 (12)	91 (11)		-7 (11)	<0.0001
Workload peak in Watts	123 (29)	108 (32)	-67 to 22	-13 (13)	<0.0001
RER peak	1.1 (0.1)	1.1 (0.1)		-3 (8)	ns
<b>Ventilatory threshold</b>					
VO <sub>2</sub> VT in ml/min/kg	12 (2)	9 (2)	-6 to 2	-22 (11)	<0.0001
%pred VO <sub>2</sub> VT	44 (9)	34 (8)	-29 to 7	-22 (11)	<0.0001
HR VT in bpm	117 (14)	106 (12)		-9 (6)	<0.0001
Workload VT in Watts	62 (19)	43 (18)	-64 to 0	-30 (19)	<0.0001

VT: ventilatory threshold; CPET: cardiopulmonary exercise test; DBP: diastolic blood pressure; HR: heart rate; pred: predicted; RER: respiratory exchange ratio; SBP: systolic blood pressure; VO<sub>2</sub>: oxygen consumption

Also, the workload at the ventilatory threshold decreased significantly in ME/CFS patients on day 2. This is in line with the present study.

**Limitations:** First, we did not include female sedentary controls for comparison in this study. Second, this was not a prospective trial, as most patients underwent consecutive day CPET for clinical management reasons. Thirdly, differences between the previously discussed studies and the present study might be in the demographic characteristics and illness severity of the study population, but also in the exact methodology of the CPET used in the different study centers. Finally, reference values for predicted VO<sub>2</sub> can differ between studies as well.

## Conclusion

This larger size study in female ME/CFS patients shows that exercise capacity expressed in peak VO<sub>2</sub>, VO<sub>2</sub> at the ventilatory threshold and workload both at peak and at the ventilatory threshold decreased significantly on day 2 compared to day 1. These results are similar to published results in female ME/CFS populations, but replication in a larger sample of studied subjects in another research center increases external validation of the results. Furthermore, we were able to show that blood pressure differences were similar in female ME/CFS patients as in male ME/CFS patients, a novel finding in literature. As known from the discussed 2 day CPET protocols in literature, showing the significant difference on day 2 in ME/CFS patients is of clinical importance in showing impairments and signs of post-exertional malaise. Further comparisons are needed to explore whether the absolute or relative changes in exercise parameters are similar or different between male and female ME/CFS patients.

## REFERENCES

- Arnett SV, Alleva LM, Korossy-Horwood R, Clark IA 2011. Chronic fatigue syndrome--a neuroimmunological model *MedHypotheses* 77:77-83
- Beaver WL, Wasserman K, Whipp BJ 1986. A new method for detecting anaerobic threshold by gas exchange *J Appl Physiol* (1985) 60:2020-2027 doi:10.1152/jappl.1986.60.6.2020
- Carruthers BM *et al.* 2011. Myalgic encephalomyelitis: International Consensus Criteria *JInternMed* 270:327-338 doi:10.1111/j.1365-2796.2011.02428.x [doi]
- Clayton EW 2015. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness *JAMA* 313:1101-1102 doi:10.1001/jama.2015.1346
- De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K 2000. Exercise capacity in chronic fatigue syndrome *ArchInternMed* 160:3270-3277
- Fluge O *et al.* 2016. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome *JCI Insight* 1:e89376 doi:10.1172/jci.insight.89376
- Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A 1994. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group *AnnInternMed* 121:953-959
- Fulcher KY, White PD 2000. Strength and physiological response to exercise in patients with chronic fatigue syndrome *JNeurolNeurosurgPsychiatry* 69:302-307
- Fulle S, Pietrangelo T, Mancinelli R, Saggini R, Fano G 2007. Specific correlations between muscle oxidative stress and chronic fatigue syndrome: a working hypothesis *JMuscle ResCell Motil* 28:355-362
- Gerrity TR *et al.* 2004. Immunologic aspects of chronic fatigue syndrome. Report on a Research Symposium

- convened by The CFIDS Association of America and co-sponsored by the US Centers for Disease Control and Prevention and the National Institutes of Health Neuroimmunomodulation 11:351-357
- Glaser S *et al.* 2010. Influence of age, sex, body size, smoking, and beta blockade on key gas exchange exercise parameters in an adult population Eur J Cardiovasc Prev Rehabil 17:469-476 doi:10.1097/HJR.0b013e328336a124
- Gur A, Oktayoglu P 2008. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment CurrPharmDes 14:1274-1294
- Hodges LD, Nielsen T, Baken D 2018. Physiological measures in participants with chronic fatigue syndrome, multiple sclerosis and healthy controls following repeated exercise: a pilot study Clin Physiol Funct Imaging 38:639-644 doi:10.1111/cpf12460
- IOM (ed) 2015. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. The National Academies Press, Washington DC
- Jammes Y, Steinberg JG, Mambrini O, Bregeon F, Delliaux S 2005. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise JIntemMed 257:299-310
- Jones DE, Hollingsworth KG, Taylor R, Blamire AM, Newton JL 2010. Abnormalities in pH handling by peripheral muscle and potential regulation by the autonomic nervous system in chronic fatigue syndrome JIntemMed 267:394-401
- Keller BA, Pryor JL, Giloteaux L 2014. Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO<sub>2</sub> peak indicates functional impairment J Transl Med 12:104 doi:10.1186/1479-5876-12-104
- Klimas NG, Salvato FR, Morgan R, Fletcher MA. 1990. Immunologic abnormalities in chronic fatigue syndrome J Clin Microbiol 28:1403-1410
- Komaroff AL, Cho TA 2011. Role of infection and neurologic dysfunction in chronic fatigue syndrome Semin Neurol 31:325-337 doi:10.1055/s-0031-1287654 [doi]
- Lien K *et al.* 2019. Abnormal blood lactate accumulation during repeated exercise testing in myalgic encephalomyelitis/chronic fatigue syndrome Physiol Rep 7:e14138 doi:10.14814/phy2.14138
- Martina JR *et al.* 2012. Noninvasive continuous arterial blood pressure monitoring with Nexfin(R) Anesthesiology 116:1092-1103 doi:10.1097/ALN.0b013e3182494ed
- McCully KK, Malucelli E, Iotti S (2006) Increase of free Mg<sup>2+</sup> in the skeletal muscle of chronic fatigue syndrome patients DynMed 5:1
- McCully KK, Smith S, Rajaei S, Leigh JS, Jr., Natelson BH 2003. Blood flow and muscle metabolism in chronic fatigue syndrome ClinSci(Lond) 104:641-647
- Naess H, Sundal E, Myhr KM, Nyland HI 2010. Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway In Vivo 24:185-188
- Naviaux RK *et al.* 2016. Metabolic features of chronic fatigue syndrome Proc Natl Acad Sci U S A 113:E5472-5480 doi:10.1073/pnas.1607571113
- Nelson MJ, Buckley JD, Thomson RL, Clark D, Kwiatek R, Davison K 2019. Diagnostic sensitivity of 2-day cardiopulmonary exercise testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome J Transl Med 17:80 doi:10.1186/s12967-019-1836-0
- Nijs J, De MK, Duquet W. 2004. Kinesiophobia in chronic fatigue syndrome: assessment and associations with disability ArchPhysMedRehabil 85:1586-1592
- Okamoto LE *et al.* 2012. Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes ClinSci(Lond) 122:183-192 doi:CS20110200 [pii];10.1042/CS20110200 [doi]
- Ortega-Hernandez OD, Shoenfeld Y. 2009. Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? AnnNYAcadSci 1173:600-609
- Paul L, Wood L, Behan WM, Maclaren WM 1999. Demonstration of delayed recovery from fatiguing exercise in chronic fatigue syndrome EurJNeurol 6:63-69
- Sargent C, Scroop GC, Nemeth PM, Burnet RB, Buckley JD 2002. Maximal oxygen uptake and lactate metabolism are normal in chronic fatigue syndrome MedSciSports Exerc 34:51-56
- Siemionow V, Fang Y, Calabrese L, Sahgal V, Yue GH 2004. Altered central nervous system signal during motor performance in chronic fatigue syndrome ClinNeurophysiol 115:2372-2381
- Sisto SA *et al.* 1996. Metabolic and cardiovascular effects of a progressive exercise test in patients with chronic fatigue syndrome AmJMed 100:634-640
- Snell CR, Stevens SR, Davenport TE, Van Ness JM. 2013. Discriminative Validity of Metabolic and Workload Measurements to Identify Individuals With Chronic Fatigue Syndrome PhysTher doi:ptj.20110368 [pii];10.2522/ptj.20110368 [doi]
- Stewart JM 2000. Autonomic nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion Pediatr Res 48:218-226 doi:10.1203/00006450-200008000-00016
- Tomas C, Brown A, Strassheim V, Elson JL, Newton J, Manning P 2018. Correction: Cellular bioenergetics is impaired in patients with chronic fatigue syndrome PLoS One 13:e0192817 doi:10.1371/journal.pone.0192817
- Van Campen CLMCV, F.C. 2020. Validity of 2-Day Cardiopulmonary Exercise Testing in Male Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Advances in Physical Education 10:68-80 doi:10.4236/ape.2020.101007
- Vanness JM, Snell CR, Stevens SR. 2007. Diminished cardiopulmonary capacity during post-exertional malaise. Journal of chronic fatigue syndrome 14:77-85
- Vermeulen RC, Kurk RM, Visser FC, Sluiter W, Scholte HR 2010. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity JTranslMed 8:93
- Vermeulen RC, Vermeulen van Eck IW 2014. Decreased oxygen extraction during cardiopulmonary exercise test in patients with chronic fatigue syndrome J Transl Med 12:20 doi:10.1186/1479-5876-12-20
- Wallman KE, Morton AR, Goodman C, Grove R. 2004. Physiological responses during a submaximal cycle test in chronic fatigue syndrome MedSciSports Exerc 36:1682-1688
- Wong R *et al.* 1992. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by <sup>31</sup>P nuclear magnetic resonance spectroscopy Chest 102:1716-1722.